An independent body should be set up to ensure the development and use of high quality clinical guidelines in prescribing support systems, says a report produced by Braxton Associates, Deloitte & Touche Consulting on behalf of the Association of the British Pharmaceutical Industry. The recommendations were presented to the Department of Health by the ABPI as its response to the Department's request for views on PRODIGY (Prescribing Rationally with Decision Support in General Practice; Marketletter November 18).
According to ABPI director general Trevor Jones, any computerised prescribing support system must have the confidence of doctors, patients and the pharmaceutical industry, and it must be based on authoritative clinical guidelines in which all parties have confidence. "The present PRODIGY pilot scheme does not meet this need," he stressed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze